Ferriprox Dosage/Direction for Use

FC tab: The amount of deferiprone to be taken will depend on the patient's weight. Ferriprox is usually prescribed as 25 mg/kg body weight, calculated to the nearest half tablet, to be taken three (3) times per day for a total daily dose of 75 mg/kg body weight. Take the first dose in the morning. Take the second dose midday. Take the third dose in the evening. It is not necessary to take Ferriprox with food. However, it may be easier to remember to take the medication, if taken with meals. Ferriprox will be most effective if the patient does not miss any doses. If the patient does miss one dose take it as soon as remembered and take the next dose at its regularly scheduled time. If the patient misses more than one dose, do not take the missed tablets, just continue with the normal schedule. Do not change the daily dose without first consulting with the doctor.
Very limited data are available on Ferriprox use in children under 6 years of age; therefore, the use of Ferriprox in this group should not be recommended unless the potential benefits outweigh the potential risks.
There are no reports of overdose with deferiprone.
Oral soln: For oral use.
Deferiprone therapy should be initiated and maintained by a physician experienced in the treatment of patients with thalassaemia.
Deferiprone is usually given as 25 mg/kg body weight, orally, three times a day for a total daily dose of 75 mg/kg body weight. Dose per kilogram body weight should be calculated to the nearest 2.5 ml. See Table 1 for recommended doses for body weights at 10 kg increments.
Doses above 100 mg/kg/day are not recommended because of the potentially increased risk of adverse reactions; chronic administration of more than 2.5 times the maximum recommended dose has been associated with neurological disorders (see Precautions, Adverse Reactions and Overdosage).
There are limited data available on the use of deferiprone in children between 6 and 10 years of age, and no data on deferiprone use in children under 6 years of age.
Due to the serious nature of agranulocytosis, that can occur with the use of deferiprone, special monitoring is required for all patients. Caution must be used when the patients' absolute neutrophil count (ANC) is low, as well as when treating patients with renal insufficiency or hepatic dysfunction. (See Precautions.)
Dose table: To obtain a dose of about 75 mg/kg/day, use the volume of oral solution suggested in the following table for the body weight of the patient. Sample body weights at 10 kg increments are listed. (See Table 1.)

Click on icon to see table/diagram/image